In recent years, the debate over net price transparency (NPT) has intensified with organisations leading calls for greater transparency of net prices in the pharmaceutical sector. In a study funded by Merck Sharp & Dohme, an expert panel coordinated by CRA developed evidence on the impact of greater NPT on innovative medicines in Europe.
Investing in health for a competitive, secure, and resilient Europe: A strategic call to action
A new report from the Partnership for Health System Sustainability and Resilience EU Expert Advisory Group, supported by CRA, calls for a more strategic and...